[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"insulin-resistance-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:insulin-resistance-syndrome":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,52,88,147,171,203,232],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100643263","sensilins-impact-of-cephalic-phase-insulin-release-induced-by-an-environmental-food-odor-stimulus-on-glucose-homeostasis-according-to-insulin-sensitivity-level-100643263",false,"NCT07638111","SENSILINS: Impact of Cephalic Phase Insulin Release Induced by an Environmental Food Odor Stimulus on Glucose Homeostasis According to Insulin Sensitivity Level","Impact of Cephalic Phase Insulin Release Induced by an Environmental Food Odor Stimulus on Glucose Homeostasis According to Insulin Sensitivity Level","SENSILNS","Inclusion Criteria\n\n* Age 18 to 50 years inclusive\n* Stable body weight during the previous 3 months (±5% of total body weight)\n* Willing to comply with the full study protocol\n* Sedentary lifestyle or stable regular physical activity, with agreement to keep this unchanged throughout the study\n* Able to understand study information, read and write French, and provide written informed consent\n* Affiliated with a social security scheme or equivalent\n* Non-smoker and non-vaper\n* Willing not to take dietary supplements, probiotics, prebiotics, or laxatives for 10 days before each visit\n* For women of childbearing potential: negative serum pregnancy test; not pregnant and not breastfeeding\n* Mean score between 1 and 2 on the 3 specific CiTAS questionnaire statements used as inclusion criteria\n* ETOC flash olfactory screening: able to detect the odor-containing vial among 4 presented vials for all 7 odors tested\n* Able to identify the madeleine odor used in the study\n* Rated pleasantness\u002Fappetence of the madeleine odor above 1\u002F9\n* For the no-overweight group: BMI 19 to \\\u003C25 kg\u002Fm² and HOMA-IR \\\u003C1.7\n* For the obesity group: BMI 30 to \\\u003C35 kg\u002Fm² and low-to-moderate insulin resistance based on HOMA-IR \\[protocol inconsistency to resolve; see note below\\]\n\nExclusion Criteria\n\n* Unstable medical or psychological conditions that could impair compliance, safety, or study participation in the investigator's judgment\n* Alcohol consumption \\>30 g\u002Fday, or established abuse\u002Fdependence on another drug\n* Ongoing exclusion period from another study listed in the national volunteer file\n* Legal protection measure (guardianship\u002Fcuratorship)\n* Deprivation of liberty by judicial or administrative decision\n* Exceeded annual compensation limit for research participation\n* Lack of valid required health documentation in the event of exceptional governmental epidemic measures\n* Blood donation within 2 months before inclusion visit\n* Limited venous access making repeated blood sampling\u002Fcatheter placement difficult\n* Current or permanent anosmia or olfactory disorder\n* Type 1 or type 2 diabetes, treated or untreated\n* History of gestational diabetes\n* Known or treated hypertension\n* Blood pressure \\>160 \\[unit missing; likely mmHg systolic threshold\\]\n* Dyslipidemia, treated or untreated\n* Triglycerides \\>3 mmol\u002FL\n* Allergic rhinitis\n* Nasosinusal polyposis\n* History of intestinal or abdominal surgery except appendectomy or simple hernia repair\n* History of ENT or neurological surgery\n* Severe eating disorder (for example anorexia, bulimia, binge-eating disorder, night eating)\n* Any pathology detected on clinical examination or medical interview judged by the investigator to interfere with study endpoints or participant safety\n* Any biological abnormality judged by the investigator to interfere with study endpoints or participant safety\n* Use of treatments likely to interfere with study measurements, for example antidepressants, antiepileptics, neuroleptics, CPAP treatment for sleep apnea, nasal spray medications, or anti-obesity drug treatment, according to investigator judgment",true,"ALL","18 Years","50 Years",{"count":22,"type":23},20,"ESTIMATED","INTERVENTIONAL",[26],"NA","This single-center, randomized, single-blind, 2-period crossover interventional study will evaluate whether exposure to a pleasant food odor 10 minutes before a 75 g oral glucose tolerance test (OGTT) modifies glucose homeostasis in adults with different metabolic phenotypes. Participants will undergo two experimental conditions in random order: food odor stimulation and control condition without odor, separated by a 4-week washout. The main objective is to quantify the within-subject effect of food odor stimulation on the incremental area under the glucose curve (iAUC) from 0 to 120 minutes during OGTT and to assess whether this effect differs according to metabolic status. Two predefined groups will be enrolled: adults without overweight and without insulin resistance, and adults with class I obesity and low-to-moderate insulin resistance. Secondary objectives include characterization of cephalic phase insulin release (CPIR), C-peptide and GLP-1 responses, glycemic kinetics, associations between CPIR and metabolic responses, and participant acceptability of the test environment and olfactory stimulation. A plasma biobank will be constituted from part of the collected samples for future research.",[29,30],"Obesity & Overweight","Insulin Resistance Syndrome",[32,33,34,35,36,37,38],"Glucose Homeostasis","Cephalic Phase Insulin Release","Food odor","Olfaction","Oral glucose tolerance test","Insulin secretion","GLP-1","NOT_YET_RECRUITING","2026-06-04",{"date":42,"type":43},"2026-06-10","ACTUAL",{"date":45,"type":23},"2026-06",{"date":47,"type":23},"2027-07",{"name":49,"class":50},"Hospices Civils de Lyon","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":51},"100639968","cf-pwv-and-tyg-index-study-100639968","NCT07589374","Cf-PWV and TyG Index Study","Correlation Between Carotid-Femoral Pulse Wave Velocity and Triglyceride-Glucose Index and Its Derived Metrics","RIGID-TyG","Inclusion Criteria:\n\n* Adults aged 18 to 65 years;\n* Both sexes;\n* Referred for ambulatory blood pressure monitoring (ABPM) as part of routine clinical evaluation;\n* Not receiving antihypertensive medication at the time of assessment;\n* Availability of valid 24-hour ABPM data;\n* Availability of carotid-femoral pulse wave velocity (cf-PWV) measurement;\n* Availability of fasting laboratory data, including glucose and triglycerides, for calculation of the triglyceride-glucose (TyG) index;\n* Ability and willingness to provide written informed consent (for prospectively recruited participants).\n\nExclusion Criteria:\n\n* Use of antihypertensive medication at the time of evaluation;\n* Cardiac arrhythmias that may interfere with accurate blood pressure or pulse wave velocity measurements;\n* Invalid or poor-quality ambulatory blood pressure monitoring (ABPM) recordings;\n* Inability to obtain reliable carotid-femoral pulse wave velocity (cf-PWV) measurements;\n* Presence of severe vascular disease or conditions affecting arterial waveform assessment;\n* Missing essential clinical, laboratory, or hemodynamic data required for the primary analysis;\n* Pregnancy;\n* Refusal or inability to provide informed consent (for prospectively recruited participants).","65 Years",{"count":62,"type":23},800,"OBSERVATIONAL","This study aims to investigate how metabolic health is related to arterial stiffness and daily blood pressure patterns. High blood pressure is one of the leading causes of heart disease worldwide, but cardiovascular risk is not determined only by average blood pressure values. Changes in blood vessel structure and metabolic function also play an important role in the development of cardiovascular disease.\n\nArterial stiffness reflects how flexible or rigid the arteries are. It can be measured using carotid-femoral pulse wave velocity (cf-PWV), which is considered a reliable and widely used method to assess vascular health. Increased arterial stiffness is associated with aging and higher cardiovascular risk.\n\nAt the same time, metabolic factors such as insulin resistance and central obesity are strongly linked to vascular damage. The triglyceride-glucose (TyG) index is a simple measure derived from routine blood tests and has been shown to reflect insulin resistance. Additional derived indices that combine TyG with body measurements (such as waist circumference and body mass index) may provide an even more comprehensive evaluation of metabolic risk.\n\nAnother important aspect of cardiovascular regulation is how blood pressure changes throughout the day. Blood pressure naturally rises in the morning after waking, a phenomenon known as the morning blood pressure surge. When this increase is excessive, it has been associated with a higher risk of cardiovascular events such as stroke and heart attack.\n\nThis study will evaluate the relationship between metabolic indices, arterial stiffness, and morning blood pressure patterns in adults undergoing ambulatory blood pressure monitoring as part of routine clinical care. The study will include both previously collected data and new participants evaluated using standardized methods.\n\nNo additional interventions will be performed, and all data will be collected as part of routine clinical evaluation. The results of this study may help improve cardiovascular risk assessment by integrating simple metabolic markers with vascular measurements and daily blood pressure behavior, potentially allowing earlier identification of individuals at higher risk.",[66,30,67,68,69],"Hypertension","Arterial Stiffness","Cardiovascular Risk","Blood Pressure Variability",[71,72,73,74,75,76,77,78],"Arterial stiffness","Pulse wave velocity","Triglyceride-glucose index","Insulin resistance","Ambulatory blood pressure monitoring","Morning blood pressure surge","Blood pressure variability","Cardiovascular risk","2026-05-19",{"date":81,"type":43},"2026-05-22",{"date":83,"type":23},"2026-07-01",{"date":85,"type":23},"2028-07-01",{"name":87,"class":50},"Hospital de Base",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":96,"targetDuration":98,"studyType":63,"phases":4,"briefSummary":99,"conditions":100,"keywords":115,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":51},"100636568","cartiz-registry-cartilage-arthropathy-and-imaging-under-tirzepatide-in-zone-stratified-cohorts---a-four-institute-mexican-observational-registry-100636568","NCT07567378","CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry","Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts (CARTIZ): A Prospective Observational Multi-Institutional Registry of the VAT-Articular-Cardiac-Aging Axis in Adults Exposed to Tirzepatide in Mexico, With Quantitative Knee Cartilage T2 Mapping, Cardiac CT Epicardial Adipose Tissue Radiomic Phenotyping, HLA Stratification, Longitudinal Multi-Frequency Bioimpedance Body Composition, and a Prespecified Surgical Tissue Acquisition Subcohort","CARTIZ","Inclusion Criteria:\n\n* 1\\. Age ≥18 years at the time of informed consent. 2. Currently receiving tirzepatide under an independent clinical indication (type 2 diabetes, insulin resistance, obesity with or without associated metabolic disease, renal protection, metabolic hypertension, or associated off-label metabolic use) prescribed by the treating physician independently of the registry.\n\n  3\\. Presence of at least one objectively documented musculoskeletal manifestation - current or historical - defined as any of: (i) inflammatory arthralgia affecting one or more joints with clinical, imaging, or serological support; (ii) CASPAR-positive psoriatic arthritis; (iii) radiographically documented knee osteoarthritis; (iv) enthesitis on physical examination or ultrasound; (v) documented inflammatory arthropathy of the spine or peripheral joints with a specialist diagnosis.\n\n  4\\. For the retrospective-prospective component: availability of clinical documentation of articular state prior to tirzepatide initiation in the patient's medical record. Documentation may include physical examination notes, imaging, laboratory values, or specialist consultation notes.\n\n  5\\. Signed informed consent for registry enrolment, longitudinal serum biobanking, HLA typing at INCMNSZ, quantitative knee MRI with T2 mapping at Ci3M UAM-Iztapalapa at Week 0 and Week 52, non-contrast cardiac CT at INCar at Week 0 and Week 52, multi-frequency bioelectrical impedance analysis at Universidad La Salle México at six timepoints, and (where applicable) medical record review. Each attestation is consented modularly within a single document.\n\n  6\\. Clinical plan to continue tirzepatide for at least 52 weeks from registry Week 0, based on the treating physician's evaluation of current clinical indication. Discontinuation during follow-up is captured as an outcome variable and does not remove the patient from the registry.\n\n  7\\. Capacity to attend scheduled follow-up visits and to undergo bilateral knee MRI at Ci3M (without severe claustrophobia requiring sedation, without absolute contraindication to MRI - see Exclusion 6) and non-contrast cardiac CT at INCar (without uncontrolled arrhythmia precluding ECG-gated imaging of diagnostic quality).\n\nFor the Surgical Tissue Subcohort (Cohort 3) only - additional criteria applied at the time of subcohort enrolment:\n\n8s. Scheduled clinically indicated cardiac surgery at the Instituto Nacional de Cardiología Ignacio Chávez (coronary artery bypass grafting, valve replacement, or combined procedures) during registry follow-up.\n\n9s. Specific additional informed consent for intraoperative collection of epicardial adipose tissue fragments.\n\nExclusion Criteria:\n\n* 1\\. Initiation or modification of a biologic disease-modifying antirheumatic drug (biologic DMARD) or JAK inhibitor within the 12 weeks prior to Week 0, or clinically anticipated initiation or modification during the first 12 weeks of follow-up. Washout may permit re-screening.\n\n  2\\. Major joint surgery within the 3 months prior to Week 0, or planned major joint surgery within the 12 months following Week 0, involving any joint scheduled for evaluation in the registry.\n\n  3\\. Intra-articular corticosteroid or hyaluronic acid injection within the 6 weeks prior to baseline biospecimen collection in any joint. Patients beyond the 6-week washout are eligible.\n\n  4\\. Active malignancy, with the exception of adequately treated non-melanoma skin carcinoma. History of malignancy in remission ≥5 years is permitted at the discretion of the treating investigator.\n\n  5\\. Current pregnancy, lactation, or planned pregnancy within the 12-month observation period.\n\n  6\\. Absolute contraindication to MRI, including non-MRI-compatible cardiac pacemaker or implanted defibrillator, ferromagnetic intracranial vascular clips, non-documented non-MRI-compatible cochlear implants, or other contraindication per the local MRI safety protocol.\n\n  7\\. Systemic rheumatologic disease other than psoriatic arthritis or osteoarthritis requiring active immunomodulation, specifically: seropositive rheumatoid arthritis on biologic therapy, active systemic lupus erythematosus on immunomodulation, active vasculitis on immunosuppression, or other systemic disease whose treatment confounds the inflammatory axis the registry is designed to characterize.\n\n  8\\. Inability to provide informed consent (cognitive impairment, language barrier not resolvable with site interpreter, or other incapacity to understand the protocol), or anticipated inability to complete the 52-week follow-up.\n\nFor the Surgical Tissue Subcohort (Cohort 3) only - additional exclusions:\n\n9s. Prior major cardiac surgery resulting in extensive pericardial adhesions that preclude safe intraoperative EAT fragment collection, as assessed by the operating cardiac surgeon.\n\n10s. Emergency cardiac surgery precluding the specific informed consent process.",{"count":97,"type":23},30,"52 Weeks","CARTIZ is a prospective observational clinical registry of adults in Mexico receiving tirzepatide (a dual GLP-1\u002FGIP receptor agonist) under an independent clinical indication - typically type 2 diabetes, insulin resistance, obesity, renal protection, metabolic hypertension, or associated off-label metabolic use. The registry is entirely observational: CARTIZ does not initiate, modify, interrupt, or supply tirzepatide, and does not dictate dose, route, or duration. All pharmacological exposure decisions are made by the treating physician independently of study participation. The registry is operationalized through a four-institute architecture integrating three Mexican National Institutes of Health and one national imaging laboratory. Core 1 (Knee Cartilage Imaging, Ci3M UAM-Iztapalapa) performs bilateral 3T MRI with quantitative T2 mapping at Week 0 and Week 52. Core 2 (Cardiac Imaging, Instituto Nacional de Cardiología Ignacio Chávez) performs non-contrast cardiac computed tomography for radiomic phenotyping of epicardial adipose tissue at Week 0 and Week 52 under cardiovascular Co-Principal Investigator Dr. Erick Alexánderson Rosas. Core 3 (HLA Typing, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Transplant Department) performs Class I and Class II HLA typing by PCR-SSO Reverse Luminex. Core 4 (Body Composition, Universidad La Salle México) performs multi-frequency bioelectrical impedance analysis (seca mBCA) at six longitudinal timepoints capturing visceral adipose tissue trajectory, phase-angle trajectory, appendicular skeletal muscle mass, and hydration ratios at zero marginal cost. The registry enrolls n=30 patients across three clinical sites with identical protocol (IMSS Clínica Río Magdalena, INCMNSZ outpatient clinic, and a private practice site in Mexico City), generating 60 evaluable knees and 30 paired cardiac CT studies. The primary co-endpoints address a mechanistic question no other tirzepatide study is positioned to answer: whether the articular response to tirzepatide in inflammatory arthropathy precedes and mechanistically precedes weight loss, through formal mediation analysis of Week-4 ACR20 response via high-sensitivity C-reactive protein, SERPINB2, and dipeptidyl peptidase-4 activity, restricted to the Mechanistic Analysis Set of patients with tirzepatide exposure ≤16 weeks at Week 0 and delta-BMI \\\u003C1.0 kg\u002Fm² through Week 4. A prespecified Surgical Tissue Subcohort is declared at initial registration to establish public scientific priority on direct human epicardial adipose tissue transcriptomic characterization under dual GIP\u002FGLP-1 receptor agonism. Subcohort participants who undergo clinically indicated cardiac surgery at INCar during follow-up (coronary artery bypass grafting, valve replacement, or combined procedures) are invited to provide specific additional informed consent for collection of epicardial adipose tissue fragments routinely excised during operative access and otherwise discarded as surgical waste. Operational launch is contingent on separate INCar tissue-specific approvals and will proceed via PRS record amendment when ready",[101,102,103,104,105,106,30,107,108,109,110,111,112,113,114],"Psoriatic Arthritis","Osteoarthitis","Knee","Diabetes (DM)","Type 2 Diabetes Mellitus (T2DM)","Obesity (Disorder)","Metabolic Syndrome","Heart Failure","Preserved Ejection Fraction","Coronary Artery Disease","Atrial Fibrillation (AF)","Non Alcholic Fatty Liver Disease","Sarcopenia","Pericardium",[116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137],"Tirzepatide","Dual GIP\u002FGLP-1 receptor agonist","Multi-nutrient-stimulated hormones","Psoriatic arthritis","Inflammatory arthropathy","ACR20","Cartilage T2 mapping","Quantitative knee MRI","Epicardial adipose tissue","Cardiac CT radiomics","Fat Attenuation Index","HLA typing","Visceral adipose tissue","Phase angle","seca mBCA","Bioelectrical impedance analysis","Mediation analysis","Weight-independent effect","Off-label exposure","Mexican registry","Epicardial adipose transcriptomics","Single-nucleus RNA sequencing","2026-05-07",{"date":140,"type":43},"2026-05-12",{"date":142,"type":23},"2026-05",{"date":144,"type":23},"2029-05",{"name":146,"class":50},"JULIO GRANADOS MONTIEL",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":24,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":162,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":169,"locationsCount":51},"100624906","artichoke-by-products-rich-in-hydroxycinnamic-acids-and-mediterranean-diet-for-type-2-diabetes-prevention-100624906","NCT07415720","Artichoke By-products Rich in Hydroxycinnamic Acids and Mediterranean Diet for Type 2 Diabetes Prevention.","Multiomic Evaluation of the Effect of Artichoke By-products Supplementation Rich in Hydroxycinnamic Acids, Integrated Into an Energy-restricted Mediterranean Diet, on the Prevention of Type 2 Diabetes.","ARTI-UP","Inclusion Criteria:\n\n* BMI between 25.0 and 35.0 kg\u002Fm²\n* HOMA-IR ≥ 2.5.\n* Adequate physical examination and vital signs or clinically irrelevant to the intervention (those not related to metabolic health).\n* Subjects must be able to understand and be willing to sign the informed consent form, and must comply with all study procedures and requirements.\n* Subjects must have a stable means of communication, either by email and\u002For telephone.\n\nExclusion Criteria:\n\n* Weight loss of more than 5% in the last 6 months prior to surgery.\n* Consumption of antibiotics in the 3 months prior to the intervention.\n* Subjects who are undergoing treatment for weight loss\u002Fbody composition modification, use medication for weight loss or blood glucose control, or have had weight loss surgery.\n* Have a medical diagnosis of type 1 or type 2 diabetes.\n* History of inflammatory bowel disease and\u002For resection of the large or small intestine. Subjects with relevant functional or structural abnormalities of the digestive system.\n* Inability to follow the recommended diet or physical exercise.\n* Unavailability in terms of time or location to attend study visits.\n* Failure to sign the informed consent form.\n* Inability to communicate with the research team.\n* Endocrine-related excess weight (except for treated hypothyroidism, at least 3 months of stable treatment).\n* Being pregnant or planning a pregnancy during the intervention period.\n* Being breastfeeding.\n* Having an allergy to artichokes.\n* Severe psychiatric illnesses that have required hospitalisation in the last 6 months.\n* Renal failure.\n* Having immunodeficiency or being HIV positive.\n* Being treated with immunosuppressive drugs or cytotoxic agents.\n* High alcohol intake: more than 14 units (women) and 20 units (men) per week.\n* Participation in another randomised clinical trial.\n* Volunteers undergoing drug treatment for less than 3 months with a stable dose\u002Fstable treatment.\n* Taking nutritional supplements (supplements: plant derivatives, for weight loss, fibre and probiotics) unless the person is willing to stop taking them for 3 months prior to the start of the trial.\n* Taking nutritional supplements (supplements: plant-derived, for weight loss, fibre and probiotics) unless the person is willing to stop taking them for the 16 weeks of the study intervention and a minimum washout period of 14 days prior to baseline measurements is guaranteed.\n* Having donated blood in the 14 days prior to the baseline visit.\n* Subjects with any type of cancer or undergoing treatment for cancer, or who have not been in remission for at least 5 years.\n* Any other condition that may interfere with adherence to the intervention.","75 Years",{"count":157,"type":23},150,[26],"The ARTI-UP study evaluates whether daily consumption of a supplement made from artichoke by-products, rich in hydroxycinnamic acids (HCAs), in combination with an energy-restricted Mediterranean diet (erMeDiet), can improve glycaemic control, reduce insulin resistance and contribute to weight loss in subjects with overweight or obesity. In addition, it seeks to understand the biological mechanisms involved using omic techniques and to establish predictive biomarkers that will enable progress towards personalised nutrition strategies.",[161,29,30],"Diabete Type 2","RECRUITING","2026-04-28",{"date":165,"type":43},"2026-04-29",{"date":142,"type":23},{"date":168,"type":23},"2027-12",{"name":170,"class":50},"Clinica Universidad de Navarra, Universidad de Navarra",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":155,"enrollmentInfo":179,"targetDuration":181,"studyType":63,"phases":4,"briefSummary":182,"conditions":183,"keywords":186,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":51},"100618818","endocare-screen-metabolic-liver-dysfunction-screening-study-100618818","NCT07336563","ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study","Development of a Database of Metabolic Cases and Prevalence of Metabolic Liver Dysfunction (MAFLD\u002FMASLD) in Individuals With Metabolic Syndrome Characteristics - Screening Study (ENDOCARE - SCREEN)","ENDOCARE-SCREE","Inclusion Criteria:\n\n* Age 18-75 years.\n* Overweight or obesity (BMI ≥ 25 kg\u002Fm²) and\u002For increased waist circumference and\u002For at least one metabolic risk factor (e.g., hypertension, dyslipidemia, impaired fasting glucose\u002Fprediabetes\u002Ftype 2 diabetes), as applicable per screening program.\n* Participation in the ENDOCARE screening program.\n* Ability to provide written informed consent, including consent for processing health-related data\n\nExclusion Criteria:\n\n* Inability to provide informed consent (e.g., significant cognitive impairment, acute severe psychiatric disorder, language barrier).\n* Pregnancy or breastfeeding.\n* Known advanced liver diseases at baseline (participants may be excluded from primary analyses and\u002For described separately, per statistical analysis plan).\n* Refusal of key screening procedures (e.g., blood sampling or liver ultrasound) preventing determination of liver status.\n* Refusal of data processing under General Data Protection Regulation (GDPR) requirements.",{"count":180,"type":23},10000,"6 Months","The ENDOCARE-SCREEN study is a single-center, observational, cross-sectional screening study designed to assess the prevalence, phenotypes, and determinants of metabolic dysfunction-associated steatotic liver disease (MASLD\u002FMAFLD) in adults with components of metabolic syndrome. Up to 10,000 participants aged ≥18 years with overweight, obesity, or metabolic risk factors will undergo standardized screening including a health questionnaire, anthropometric measurements, blood pressure assessment, laboratory testing, and liver ultrasound. The study aims to generate a comprehensive metabolic-hepatic dataset integrating clinical, laboratory, imaging, and lifestyle data. Collected data will be used to identify metabolic and behavioral risk factors for MASLD, characterize disease phenotypes, and support the development of predictive models. The ENDOCARE-SCREEN study will also serve as a qualification platform for selecting eligible participants for a subsequent interventional randomized controlled trial (ENDOCARE-SUPPORT). The study involves minimal risk procedures routinely used in clinical practice and follows ethical principles outlined in the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines.",[184,107,29,185,30],"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) \u002F Nonalcoholic Steatohepatitis (NASH)","Obesity Type 2 Diabetes Mellitus",[187,188,189,190,191,192,193],"MASLD","MAFLD","Metabolic syndrome","Liver steatosis","Screening","Ultrasound","Metabolic health","2026-01-13",{"date":196,"type":43},"2026-01-15",{"date":198,"type":23},"2026-01-05",{"date":200,"type":23},"2026-10-31",{"name":202,"class":50},"Jarosław Drobnik",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":17,"sex":18,"minAge":209,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":24,"phases":212,"briefSummary":213,"conditions":214,"keywords":217,"overallStatus":162,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":51},"100609953","prescription-of-step-counts-for-targeted-changes-in-body-composition-and-cardiometabolic-risk-in-overweightobese-adults-100609953","NCT07221279","Prescription of Step Counts for Targeted Changes in Body Composition and Cardiometabolic Risk in Overweight\u002FObese Adults","Inclusion Criteria:\n\n* ages of 20 years and older\n* otherwise healthy adults on prescription medication to treat hypertension or osteoarthritic conditions are eligible to participate\n* sedentary people, or people who report engaging in regular walking (no regular structured exercise for at least the past six months)\n* relatively stable weight over the previous 6 months (less than 5% fluctuation in body weight)\n\nExclusion Criteria:\n\n* any diagnosed cardiovascular, metabolic, renal, or pulmonary disease, or any diagnosed cognitive dysfunction\n\n  * women who are pregnant or plan on becoming pregnant\n  * people taking prescription medication to regulate plasma glucose, or that affect metabolism (e.g., thyroid medication)\n  * people who have undergone an increase or decrease in body weight of ≥ 5% over the previous six months\n  * current smokers\n  * people who have engaged in a program of structured exercise other than walking (e.g., weight training, jogging, swimming, cycling) within that last six months\n  * older adults (60-plus years old) who score \\> 4 on the Short Blessed Test for geriatric cognitive impairment during the first lab visit will be ineligible to participate","20 Years",{"count":211,"type":23},200,[26],"The prevalence of overweight and obesity remains epidemic in the United States, with some of the highest rates seen in older adults. While this phenomenon is certainly multifactorial, a good deal of evidence suggests that insufficient physical activity (PA) contributes significantly. Pilot data recently collected in a laboratory indicates a strong, inverse relationship between daily step counts and body fatness and cardiometabolic risk (CMR) factors when step counts are expressed relative to fat mass in young adults. This expression of PA may be especially predictive of body composition because it is influenced by factors that influence appetite and energy intake, energy expenditure, and the energy \"reservoir\" that is represented by body fat stores, all three elements of the \"settling point\" model of body weight. The strength of this relationship suggests that prescription of step counts that consider current body weight and composition, and weight loss goal, may yield predictable changes in weight and CMR in adults eating ad libitum. The long-term objective of this study is to quantify the relationship between daily step counts and body composition in young, middle aged, and older adults who are overweight\u002Fobese and develop a regression model that can be used to prescribe physical activity (daily step counts) for achieving a specific target body weight and predictably improving CMR risk for young, middle-aged, and older adult men and women over eight months while eating ad libitum. To achieve this objective, investigators will undertake two specific aims: 1) quantify the relationship between average steps·kg fat mass-1·day-1 and body composition\u002FCMR profiles in healthy, overweight, and obese adults 20-39 years, 40-59 years, 60-79 years, and 80-plus years old, using inexpensive, widely available triaxial pedometers while eating ad libitum, and 2) quantify the efficacy of employing targeted step counts expressed as steps·kg fat mass-1·day-1 using the model developed in Aim 1 for producing predictable improvements in body composition and CMR factors in overweight and obese adults 20-39, 40-59, 60-79, and 80-plus years old, over 8 months while eating ad libitum. This study will result in a regression model that may significantly improve the way that PA is prescribed for weight management, with vast clinical and public health implications.",[215,30,66,216,29],"Dyslipidemia","Inflammation Chronic",[218,219,220,221,222],"weight management","cardiometabolic risk management","physical activity","walking","pedometry","2025-10-23",{"date":225,"type":43},"2025-10-27",{"date":227,"type":43},"2025-01-13",{"date":229,"type":23},"2027-08-31",{"name":231,"class":50},"Kennesaw State University",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":239,"minAge":240,"maxAge":60,"enrollmentInfo":241,"targetDuration":4,"studyType":24,"phases":243,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":162,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":252,"leadSponsor":254,"locationsCount":51},"100578057","phase-1-hyperbaric-oxygen-therapy-on-insulin-resistance-in-postmenopause-100578057","NCT06806345","Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause","Effect of Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopausal Women","Inclusion Criteria:\n\n* A)Inclusion Criteria\n\n  * All females were clinically diagnosed with Postmenopausal Insulin resistance.\n  * Their ages were ranged from 55-65 years old.\n  * Their BMI was 30-34.9 kg\u002Fm².\n  * All patients should had controlled blood glucose levels by oral hypoglycemic drugs.\n  * All patients should had cardiac Ejection Fraction \\>or =50%.\n  * Their Chest X-ray reported normal.\n  * Their Ear ,nose , thorax will be clinically evaluated by a specialized ENT physician to ensure fitting for hyperbaric chamber\n  * Voluntary acceptance of participation in the study .\n\nB)Exclusion Criteria:\n\nParticipants will be excluded if they have :\n\n* Chronic obstructive pulmonary disease.\n* Cardiac pacemakers.\n* Epileptic fits.\n* Physically disable .\n* Any disorder that lead to ulcers other than diabetes such as ahistory of chronic peripheral arterial disease.\n\nExclusion Criteria:\n\n\\-","FEMALE","55 Years",{"count":242,"type":23},40,[244,245],"PHASE1","PHASE2","Background: In postmenopausal females, Insulin resistance is commonly encountered in clinical setting. Hyperbaric oxygen therapy have been proposed effective in lowering blood glucose level and improving function. Identification of clinical examination variables as predictors to blood glucose levels and dysfunction would offer therapists the chance to undertake clinical decisions and consequently improve treatment efficiency.\n\nObjectives: This Predictive validity, diagnostic study conduct to examine the effect of hyperbaric oxygen therapy on insulin resistance in postmenopausal women.",[30],"2025-01-28",{"date":250,"type":43},"2025-02-04",{"date":248,"type":23},{"date":253,"type":23},"2025-04-28",{"name":255,"class":50},"Cairo University"]